Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)

Keros Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $16.0 million for Q4 2025.

• Quarterly Accumulated Expenses fell 23.15% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (down 23.15% YoY) and the FY2025 annual result came in at $16.0 million, down 23.15% from the prior year.
• Accumulated Expenses was $16.0 million for Q4 2025 at Keros Therapeutics, up from $15.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $22.2 million in Q3 2024 and bottomed at $5.5 million in Q1 2021.
• A 5-year average of $12.6 million and a median of $12.5 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses soared 87.71% — and 2025, when it tumbled 31.55%.
• Keros Therapeutics' Accumulated Expenses stood at $7.3 million in 2021, then soared by 73.77% to $12.8 million in 2022, then surged by 40.5% to $17.9 million in 2023, then rose by 16.48% to $20.9 million in 2024, then decreased by 23.15% to $16.0 million in 2025.
• Business Quant data shows KROS's Accumulated Expenses at $16.0 million in Q4 2025, $15.2 million in Q3 2025, and $20.0 million in Q2 2025.